JP2012508172A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508172A5
JP2012508172A5 JP2011534887A JP2011534887A JP2012508172A5 JP 2012508172 A5 JP2012508172 A5 JP 2012508172A5 JP 2011534887 A JP2011534887 A JP 2011534887A JP 2011534887 A JP2011534887 A JP 2011534887A JP 2012508172 A5 JP2012508172 A5 JP 2012508172A5
Authority
JP
Japan
Prior art keywords
factor according
coagulation factor
starch
amino acid
coagulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011534887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508172A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/063151 external-priority patent/WO2010062768A1/en
Publication of JP2012508172A publication Critical patent/JP2012508172A/ja
Publication of JP2012508172A5 publication Critical patent/JP2012508172A5/ja
Pending legal-status Critical Current

Links

JP2011534887A 2008-11-03 2009-11-03 血友病の治療方法 Pending JP2012508172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11080908P 2008-11-03 2008-11-03
US61/110,809 2008-11-03
PCT/US2009/063151 WO2010062768A1 (en) 2008-11-03 2009-11-03 Method for the treatment of hemophilia

Publications (2)

Publication Number Publication Date
JP2012508172A JP2012508172A (ja) 2012-04-05
JP2012508172A5 true JP2012508172A5 (enExample) 2012-12-20

Family

ID=42225997

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534887A Pending JP2012508172A (ja) 2008-11-03 2009-11-03 血友病の治療方法

Country Status (7)

Country Link
US (1) US20120027743A1 (enExample)
EP (1) EP2352515A4 (enExample)
JP (1) JP2012508172A (enExample)
KR (1) KR20110093775A (enExample)
CN (1) CN102202684A (enExample)
CA (1) CA2740793A1 (enExample)
WO (1) WO2010062768A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101821E (pt) 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
TW201731488A (zh) 2007-12-28 2017-09-16 巴克斯歐塔公司 重組vwf調配物
HRP20130414T1 (en) 2008-10-21 2013-06-30 Baxter International Inc. Lyophilized recombinant vwf formulations
SI2393828T1 (sl) 2009-02-03 2017-01-31 Amunix Operating Inc. Podaljšani rekombinantni polipetidi in sestavki, ki jih obsegajo
US20110046060A1 (en) 2009-08-24 2011-02-24 Amunix Operating, Inc., Coagulation factor IX compositions and methods of making and using same
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
DK2654794T3 (da) 2010-12-22 2020-06-08 Baxalta GmbH Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
NZ628014A (en) 2012-02-15 2016-09-30 Biogen Ma Inc Recombinant factor viii proteins
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
JP2015519313A (ja) 2012-04-24 2015-07-09 ノヴォ ノルディスク アー/エス 血友病の治療に適する医薬組成物
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
JP7763589B2 (ja) 2018-05-18 2025-11-04 バイオベラティブ セラピューティクス インコーポレイテッド 血友病aを処置する方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IL113010A0 (en) * 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US8465468B1 (en) * 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
CA2788505C (en) * 2003-02-26 2018-09-04 Nektar Therapeutics Polymer-factor viii moiety conjugates
US7632921B2 (en) * 2004-11-12 2009-12-15 Bayer Healthcare Llc Site-directed modification of FVIII
WO2006103298A2 (en) * 2005-04-01 2006-10-05 Novo Nordisk Health Care Ag Blood coagulation fviii analogues
WO2008081024A1 (en) * 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
WO2008119815A1 (en) * 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix

Similar Documents

Publication Publication Date Title
JP2012508172A5 (enExample)
JP2013519636A5 (enExample)
Chang et al. Amphiphilic hydrogels for biomedical applications
Kadajji et al. Water soluble polymers for pharmaceutical applications
Lee et al. PLA micro-and nano-particles
Nita et al. New trends in bio-based aerogels
JP2018040002A5 (enExample)
Chan et al. Pectin as a rheology modifier: Origin, structure, commercial production and rheology
Moscovici Present and future medical applications of microbial exopolysaccharides
JP2018535704A5 (enExample)
JP2008516735A5 (enExample)
JP2015527411A5 (enExample)
JP2017511322A5 (enExample)
JP2012506904A5 (enExample)
JP2015516240A5 (enExample)
Mndlovu et al. Bioplatform fabrication approaches affecting chitosan-based interpolymer complex properties and performance as wound dressings
JP2010537989A5 (enExample)
CA2389251A1 (en) Swelling and deswelling polymer blends
Das et al. A polysaccharide-based pH-sensitive hybrid hydrogel as a sustained release matrix for antimicrobial drugs
Youn et al. Tissue adhesives based on chitosan for biomedical applications
JP2011513393A5 (enExample)
Neamtu et al. Nanogels containing polysaccharides for bioapplications
Fatima et al. Diversity of rationally modified polysaccharides for pharmaceutical applications
Abdel-Rahman et al. Hyaluronan/Zinc oxide nanocomposite-based membrane: preparation, characterization, and in vitro and in vivo evaluation
Cheng et al. Grafted polysaccharides as advanced pharmaceutical excipients